Actively Recruiting

Phase Not Applicable
Age: 18Years - 99Years
All Genders
NCT06425380

Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

Led by Mayo Clinic · Updated on 2026-01-30

11

Participants Needed

2

Research Sites

132 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research is studying how a food product (resistant potato starch) which is a dietary supplement made from potato starch affects the gut bacteria of people with cirrhosis and hepatic encephalopathy. The researchers in this study want to understand how potato starch works in the subject's body and how the body will react to it. Along with taking the study product participants health-related information and stool will be collected for this research study.

CONDITIONS

Official Title

Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

Who Can Participate

Age: 18Years - 99Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to provide signed and dated informed consent.
  • Willing to comply with all study procedures and be available for the study duration.
  • Diagnosis of cirrhosis confirmed by liver biopsy, imaging, or clinical decompensation.
  • History of at least one overt Hepatic Encephalopathy episode in the last year (West Haven Grades II to IV), including precipitated episodes.
  • Sexually active women of childbearing potential must agree to use a highly-effective contraception method during the study.
Not Eligible

You will not qualify if you...

  • Hospitalization within the last 4 weeks.
  • Current refractory ascites requiring large volume paracentesis.
  • Use of gut-absorbable or intravenous antibiotics in the last 4 weeks (except rifaximin).
  • Planned antibiotic use in the next 4 weeks.
  • Use of lactulose in the last 4 weeks.
  • Alcohol or illicit drug use in the last 4 weeks (more than 1 alcoholic drink per week).
  • History of inflammatory bowel disease.
  • History of primary sclerosing cholangitis.
  • Total bilirubin > 4 mg/dL in the last 3 months.
  • Prior diagnosis of dementia or other primary neurocognitive disorder.
  • Pregnancy or breastfeeding.
  • Portosystemic shunt or transjugular intrahepatic portosystemic shunt placed within the last 3 months.
  • Allergy to resistant potato starch.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Mayo Clinic

Rochester, Minnesota, United States, 55902

Actively Recruiting

2

Mayo Clinic

Rochester, Minnesota, United States, 55905

Actively Recruiting

Loading map...

Research Team

J

Jenny Obst

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here